Suzanne Ostrand‐Rosenberg

31.9k citations

156 papers · 24.5k indexed · 12 hit papers · h-index 58

Impact in

Immunology top 0.02%
- Immune cells in cancer
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Immune Response and Inflammation
- T-cell and B-cell Immunology
Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Cells and Metastasis

Papers in

Immunology 141
- Immunotherapy and Immune Responses 75
- Immune cells in cancer 63
- Immune Cell Function and Interaction 45
- Immune Response and Inflammation 27
- T-cell and B-cell Immunology 25
Oncology 63
- Cancer Immunotherapy and Biomarkers 29
- Inflammatory Biomarkers in Disease Prognosis 18
- CAR-T cell therapy research 17

Co-authors: Pratima Sinha Virginia K. Clements Dmitry I. Gabrilovich Vincenzo Bronte Beth A. Pulaski Robert H. Vonderheide Stephanie K. Bunt Daniel W. Beury
Journals: The Journal of Immunology (36 papers)Cancer Immunology Immunotherapy (14 papers)Cellular Immunology (11 papers)Cancer Research (10 papers)Journal of Proteome Research (6 papers)
Partner nations: United States Germany Canada

In The Last Decade

Suzanne Ostrand‐Rosenberg

156 papers receiving 24.2k citations

Hit Papers

12 papers align trajectories log scale

Understanding the tumor immune microenvironment (TIME) for effective therapy 2018 · 4.0k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Nature Medicine
2018 The Journal of Immunology
2016 Nature Communications
2015 Advances in cancer research
2012 Nature reviews. Immunology
2009 Cancer Research
2009 The Journal of Immunology
2008 The Journal of Immunology
2007 Cancer Research
2007 Cancer Research
2007 The Journal of Immunology
2000 Current Protocols in Immunology

Peers

Countries citing papers authored by Suzanne Ostrand‐Rosenberg

Since Specialization

Citations

This map shows the geographic impact of Suzanne Ostrand‐Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Ostrand‐Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Ostrand‐Rosenberg more than expected).

Fields of papers citing papers by Suzanne Ostrand‐Rosenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Ostrand‐Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Ostrand‐Rosenberg. The network helps show where Suzanne Ostrand‐Rosenberg may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Suzanne Ostrand‐Rosenberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Suzanne Ostrand‐Rosenberg Line = papers co-authored together Suzanne Ostrand‐Rosenberg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Defining myeloid-derived suppressor cells Nature reviews. Immunology ·Leila Akkari, Ido Amit, Vincenzo Bronte, Zvi G. Fridlender, Dmitry I. Gabrilovich, Florent Ginhoux, Catherine C. Hedrick, Suzanne Ostrand‐Rosenberg	2024	17
2	Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus Journal of Clinical Investigation ·Anca Dorhoi, Leigh A. Kotzé, Jay A. Berzofsky, Yongjun Sui, Dmitry I. Gabrilovich, Ankita Garg, Richard Hafner, Shabaana A. Khader, Ulrich E. Schaible, Stefan H. E. Kaufmann, Gerhard Walzl, Manfred B. Lutz, 純一折田, Suzanne Ostrand‐Rosenberg, William R. Bishai, Nelita du Plessis	2020	34
3	Top-Down Proteomic Characterization of Truncated Proteoforms Journal of Proteome Research ·Dapeng Chen, Lucía Geis‐Asteggiante, Fábio Pereira Gomes, Suzanne Ostrand‐Rosenberg, Catherine Fenselau	2019	15
4	Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes Cancer Immunology Research ·Lucas A. Horn, Tiha M. Long, А.В. ЯКОВЛЕВА, Virginia K. Clements, Suzanne Ostrand‐Rosenberg	2017	28
5	A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing Programmed Death Ligand-1 and Simultaneously Providing Costimulation Cancer Immunology Research ·Samuel Haile, Lucas A. Horn, Suzanne Ostrand‐Rosenberg	2014	36
6	HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells Cancer Research ·Katherine H. Parker, Pratima Sinha, Lucas A. Horn, Virginia K. Clements, Huan Yang, Jianhua Li, Kevin J. Tracey, Suzanne Ostrand‐Rosenberg	2014	208
7	IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development Cancer Discovery ·Courtney Smith, Mee Young Chang, Katherine H. Parker, Daniel W. Beury, James B. DuHadaway, S. Mohlman, Janette Boulden, Erika Sutanto‐Ward, Alejandro Peralta Soler, Lisa D. Laury‐Kleintop, Laura Mandik‐Nayak, Richard Metz, Suzanne Ostrand‐Rosenberg, George C. Prendergast, Alexander J. Muller	2012	260
8	Tumor cell Programmed Death Ligand-1-mediated T cell suppression is overcome by co-expression of CD80 (66.29) The Journal of Immunology ·Samuel Haile, Doris M Alvarado, Cruickshank, H.; Wray, J.; Scull, D. [Public Service Electric & Gas, Hancock`s Bridge, NJ (United States)], Minu K. Srivastava, Ll Dagmar Coester-Waltjen, Julie Wolf, Bruce R. Ksander, Suzanne Ostrand‐Rosenberg	2011	1
9	Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine Cancer Research ·Minu K. Srivastava, Pratima Sinha, Virginia K. Clements, Paulo C. Rodrı́guez, Suzanne Ostrand‐Rosenberg Hit paper breakdown →	2009	759
10	Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer The Journal of Immunology ·Suzanne Ostrand‐Rosenberg, Pratima Sinha Hit paper breakdown →	2009	1390
11	Tumor-Specific CD4+ T Cells Are Activated by “Cross-Dressed” Dendritic Cells Presenting Peptide-MHC Class II Complexes Acquired from Cell-Based Cancer Vaccines The Journal of Immunology ·Brian P. Dolan, Kenneth D. Gibbs, Suzanne Ostrand‐Rosenberg	2006	76
12	Dendritic Cells Cross-Dressed with Peptide MHC Class I Complexes Prime CD8+ T Cells The Journal of Immunology ·Brian P. Dolan, Kenneth D. Gibbs, Suzanne Ostrand‐Rosenberg	2006	122
13	Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression The Journal of Immunology ·Stephanie K. Bunt, Pratima Sinha, Virginia K. Clements, Jeff Leips, Suzanne Ostrand‐Rosenberg	2006	447
14	Presentation of Endogenously Synthesized MHC Class II-Restricted Epitopes by MHC Class II Cancer Vaccines Is Independent of Transporter Associated with Ag Processing and the Proteasome The Journal of Immunology ·Samudra K. Dissanayake, Yusan Chen, Suzanne Ostrand‐Rosenberg	2005	32
15	Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease The Journal of Immunology ·Pratima Sinha, Virginia K. Clements, Suzanne Ostrand‐Rosenberg	2005	359
16	Invariant Chain and the MHC Class II Cytoplasmic Domains Regulate Localization of MHC Class II Molecules to Lipid Rafts in Tumor Cell-Based Vaccines The Journal of Immunology ·Brian P. Dolan, Maria Miguel Carvalho Rocha Pinto de Sousa, Dan Ilkovitch, Ling Qi, William F. Wade, Terri M. Laufer, Suzanne Ostrand‐Rosenberg	2004	7
17	Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-γ Dependent The Journal of Immunology ·Suzanne Ostrand‐Rosenberg, Virginia K. Clements, Masaki Terabe, Jong Myun Park, Jay A. Berzofsky, Samudra K. Dissanayake	2002	95
18	H2-O Inhibits Presentation of Bacterial Superantigens, but Not Endogenous Self Antigens The Journal of Immunology ·Ling Qi, Suzanne Ostrand‐Rosenberg	2001	14
19	Tumor Cells Present MHC Class II-Restricted Nuclear and Mitochondrial Antigens and Are the Predominant Antigen Presenting Cells In Vivo The Journal of Immunology ·Ling Qi, José M. Rojas, Suzanne Ostrand‐Rosenberg	2000	54
20	Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection. The Journal of Immunology ·Esi Lamousé‐Smith, Virginia K. Clements, Suzanne Ostrand‐Rosenberg	1993	48

About Suzanne Ostrand‐Rosenberg

Suzanne Ostrand‐Rosenberg is a scholar working on Immunology, Oncology, Clinical Biochemistry, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 156 papers that have together received 24.5k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (75 papers), Immune cells in cancer (63 papers), Immune Cell Function and Interaction (45 papers), Cancer Immunotherapy and Biomarkers (29 papers), Immune Response and Inflammation (27 papers), T-cell and B-cell Immunology (25 papers), Inflammatory Biomarkers in Disease Prognosis (18 papers) and CAR-T cell therapy research (17 papers). The work is most often cited by research in Immunology (17.7k citations), Oncology (10.8k citations), Cancer Research (2.4k citations), Biological Psychiatry (307 citations) and Neurology (788 citations). Suzanne Ostrand‐Rosenberg has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Pratima Sinha, Virginia K. Clements, Dmitry I. Gabrilovich, Vincenzo Bronte, Beth A. Pulaski, Robert H. Vonderheide, Stephanie K. Bunt, Daniel W. Beury, Paulo C. Rodrı́guez and Catherine Fenselau. Their work appears in journals such as The Journal of Immunology, Cancer Immunology Immunotherapy, Cellular Immunology, Cancer Research and Journal of Proteome Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact